Inhibitec Anticuerpos

Logo Inhibitec

Contact information

Gabriel Mesquida
C/ Albert Einstein 14
+34 670 78 59 69
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Drug development
      • Drug discovery
    • Therapeutic areas
      • Dermatology
      • Inflammatory diseases
      • Immunology

INHIBITEC Anticuerpos S.L. is a pre clinical and clinical stage biotechnology company founded in 2019 in Santander, (Cantabria), Spain, focused on the development of a therapeutic monoclonal antibody (mAB) to be used in cure of autoimmune diseases and more specifically in Psoriasis and Psoriasic Arthritis. 

Our technology is based in a patent owned by the Spanish National Research Council (CSIC) and the Universidad de Cantabria (UC), filled in 2015. 

Our approach is a novel pathway to increase the efficacy vs current therapies for the treatment of Psoriasis and Psoriatic Arthritis

Products and services

Our monoclonal antibody (mAb) works against BAMBI (BMP and Activin Membrane-Bound Inhibitor). BAMBI is a transmembrane molecule that inhibits a key signal pathway that controls two lymphoid subpopulations with opposed roles in the pathogenesis of autoimmune diseases.

Areas of interest for future collaborations

Immunotherapies; Non clinical and clinical studies; dermatological and rheumatic diseases